Volume 14 Issue 1, March 2020

Medivir is developing tumor-directed nucleotide oral prodrugs to treat cancers with highly unmet medical needs. The company’s lead drug candidate, MIV-818, is a liver cancer targeted prodrug that Medivir is looking to develop alone in the USA and the EU and through partnerships elsewhere.

By supporting research, development and licensing behind its portfolio of companies KDDF is translating Korean science into breakthrough oncology treatments.

Seoul-based WellMarker Bio is developing a deep pipeline of first-in-class drugs guided by comprehensive biomarker analysis.

Light Chain Bioscience is leveraging its proprietary bispecific antibody format to advance immune therapies in oncology and beyond

Using its proprietary PREDATOR protein engineering platform, Werewolf designs biotherapeutics that are systemically delivered and activated selectively in the tumor microenvironment to recruit a powerful antitumor immune response.

Immuno-oncology company Affimed is harnessing the power of innate immunity, with the help of its ROCK (Redirected Optimized Cell Killing) platform to change the lives of patients with cancer

Gastrointestinal cancers present a huge unmet medical need. Arbele is working to bring cutting-edge immunotherapy to these patients.

VCN Biosciences is developing a highly selective, advanced generation of oncolytic adenoviruses.

M&A activity in the biopharma industry continued to boom last year, with more than 200 deals collectively worth over $200 billion.

By harvesting stem cells from umbilical cord blood and differentiating them into natural killer cells, Glycostem has developed oNKord, an affordable off-the-shelf cell therapy product indicated for oncology therapies that is ready to ship worldwide within 48hours